Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results - NNT in Strive section. This Correction article states the incorrect and correct sentence.

Correction to Schultz et al. BMC Urology (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.

Incorrect:

The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Correct:

The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.